Low back pain overview

Jump to navigation Jump to search

```

Low back pain Microchapters

Home

Overview

Pathophysiology

Causes

Differentiating Low back pain from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Conservative Management

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Low back pain overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Low back pain overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Low back pain overview

CDC on Low back pain overview

Low back pain overview in the news

Blogs on Low back pain overview

Directions to Hospitals Treating Low back pain

Risk calculators and risk factors for Low back pain overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Keanu Ngo[2]

Overview

This chapter addresses low back pain (LBP) in adults in outpatient settings. Pediatric, pregnancy-related, post-traumatic, postoperative, and cancer-related LBP are covered elsewhere.

LBP is pain below the costal margin and above the inferior gluteal folds, with or without leg pain.[1] It is the leading cause of years lived with disability worldwide and affects people of all ages.[2] The Global Burden of Disease Study estimated 619 million prevalent cases in 2020, projected to reach 843 million by 2050. Of LBP-related years lived with disability, 38.8% were attributed to occupational factors, smoking, and high BMI.[3] Mean lifetime prevalence in adults is approximately 40%, and mean point prevalence is approximately 12%.[1] Age-standardized prevalence is higher in females (9330 vs 5520 per 100 000) and rises with age, peaking at about 85 years.[2]

LBP is a symptom syndrome rather than a single disease. About 90% of patients presenting for care have nonspecific LBP, defined as pain without a specific spinal disorder (radiculopathy, spinal stenosis, vertebral fracture, axial spondyloarthritis, infection, or malignancy) and without referred pain from nonspinal structures.[2] The NEJM review gives 80–90%.[1] Nonspecific LBP is understood as arising from interacting biological, psychological, social, and occupational factors rather than a single pathoanatomical lesion.[2]

Recent reviews classify duration as acute (<6 weeks), subacute (6–12 weeks), and chronic (>12 weeks).[2] The American College of Physicians (2017) defines acute as <4 weeks and subacute as 4–12 weeks, and other guidelines use <4, <6, or <12 weeks for acute LBP.[4] See Low back pain classification.

Serious spinal pathology is uncommon in primary care. Cauda equina syndrome affects about 0.1% of patients presenting to primary care.[2] In one primary care cohort of 1172 patients with acute LBP, 0.9% had a serious spinal condition (mostly fractures) over 1 year.[1] Individual red flags have limited accuracy. The stronger predictors are cancer history, saddle anesthesia, urinary retention, procedure-related infection, and age.[5] A history of cancer raises the posttest probability of spinal malignancy to 33% (95% CI, 22%–46%).[2]

Acute nonspecific LBP is usually self-limited, with about 72% of patients recovering by 12 months. About 42% of patients with chronic nonspecific LBP recover within 12 months.[2] Detail belongs in Low back pain natural history, complications and prognosis.

Initial management at any duration consists of reassurance that serious disease is unlikely, discussion of the expected course, advice to remain active and continue usual activities including work, and self-management support. Routine imaging is not recommended for nonspecific LBP and is reserved for severe or progressive neurological deficit or features of serious disease.[2]

Red flags and emergency recognition

Red flags are grouped by suspected condition. Each has limited individual accuracy, and multiple features increase concern for serious pathology and the need for further evaluation such as MRI.[2][5]

  • Fracture: major trauma; minor trauma with age >50 years, osteoporosis, or corticosteroid use.[6]
  • Malignancy: prior cancer, unexplained weight loss, age >50 years, pain at rest or at night, failure to improve with treatment.[6]
  • Infection: fever, intravenous drug use, immunosuppression, penetrating wound, recent infection or spinal procedure, spinal tenderness.[6][2]
  • Axial spondyloarthritis (consider): insidious onset before age 45 years, morning stiffness of at least 30 minutes, improvement with exercise but not rest, alternating buttock pain, night waking from back pain.[2]
  • Cauda equina syndrome: new urinary retention or incontinence, saddle anesthesia, and progressive lower-extremity weakness require immediate MRI and urgent neurosurgical evaluation.[2]

Diagnostic triage framework

  • Across 15 primary care guidelines reviewed in 2018, the usual approach is triage into nonspecific LBP, radiculopathy/sciatica, and specific (serious) LBP, using history and examination for red flags, neurological testing for radicular syndrome, and assessment of psychosocial (yellow flag) factors.[7]
  • Nonspinal causes (hip disease, pelvic organ disease, aortic aneurysm, renal and gastrointestinal disease) are detailed in Low back pain differentiating diagnosis.
  • Cause lists, radiculopathy prevalence, and axial spondyloarthritis prevalence are detailed in Low back pain causes and Low back pain epidemiology and demographics.

Prognosis and imaging headlines

  • In acute LBP, maladaptive pain coping behaviors, low general health status, and psychiatric comorbidity were associated with persistent disabling LBP.[5]
  • RCTs of early imaging versus no imaging found no difference in pain or function in patients without signs of serious spine pathology.[5]
  • Routine radiography, CT, or MRI does not improve outcomes and may produce incidental findings that lead to further testing and unnecessary interventions.[2]

Management headlines

Details, doses, and monitoring belong in Low back pain medical therapy.

Statement Evidence type and strength
Acute: NSAIDs, skeletal muscle relaxants, manipulation/mobilization, acupuncture, advice to stay active, and early physical therapy referral improved pain and/or function Systematic review for guideline development; moderate confidence[5]
Acute: acetaminophen did not improve pain or disability versus placebo; not recommended as single therapy Cochrane overview (high certainty)[8][2]
Acute: opioids similar to placebo for pain and function (low confidence), with higher risk of adverse events (moderate confidence); reserve for severe, disabling pain unresponsive to NSAIDs and muscle relaxants, as a short course of an immediate-release formulation Systematic review; narrative expert review[5][2]
Acute: benzodiazepines and systemic corticosteroids are not recommended for nonspecific LBP Narrative expert review citing trials and meta-analysis[2]
Acute: exercise-specific trials were mixed, and early physical therapy referral (which included exercise) improved outcomes Systematic review[5]
Chronic: exercise, psychological therapies (e.g., CBT), or combined multidisciplinary care first; NSAIDs as the first medication if drug therapy is needed Narrative expert review; ACP guideline summary[2][9]
Radiculopathy: systemic steroids (low confidence) and epidural steroid injections improved function; epidural steroid injections also improved back pain Systematic review[5]

Effect sizes are generally small, and benefits tend to appear within the first few weeks. Serious or long-term harms were not well assessed in trials.[5]

Safety essentials:

  • NSAIDs: use caution with asthma, kidney disease, prior ulcer, and antihypertensive or antithrombotic coprescription. Contraindications include chronic kidney disease and active gastrointestinal bleeding.[2]
  • Skeletal muscle relaxants increase adverse events (dizziness, drowsiness). Contraindications include high fall risk in older adults, glaucoma, and significant heart, liver, or kidney disease.[2]

Clinically actionable recommendations

  1. Classify the presentation as nonspecific, radicular, or suspected specific/serious cause, and note duration and the duration cutoff used.
  2. Screen for condition-specific red flags (above) and for severe or progressive neurological deficit. Image promptly for suspected cauda equina syndrome, severe or progressive deficit, recent significant trauma, or features of cancer, infection, or fracture. Individual red flags have limited diagnostic value, and multiple features should increase concern and prompt further evaluation such as MRI.[2][5]
  3. Assess yellow flags (maladaptive coping, depression, anxiety, low general health, work-related factors) early.[7]
  4. For nonspecific LBP without red flags, avoid routine imaging at any duration. Provide education, advice to stay active, and nonpharmacologic therapy or NSAIDs as needed, and reassess the diagnosis if pain persists.[2]
  5. Pain persisting beyond 8 weeks despite appropriate therapy warrants reassessment, including imaging and laboratory evaluation aimed at identifying a specific cause.[10]
  6. Advise against prolonged bed rest, encourage activity, and provide self-management strategies such as heat.[2][7]
  7. Refer urgently for cauda equina syndrome or progressive deficit. Refer for suspected serious pathology, radiculopathy, or failure to improve; the "no improvement" threshold varies from 4 weeks to 2 years across guidelines.[7]

Important updates compared with older teaching

  • Biopsychosocial rather than structural model: nonspecific LBP is multifactorial, and structural findings poorly explain symptoms.[2]
  • Activity over rest: prolonged bed rest is discouraged.[7]
  • Imaging restraint: early imaging does not improve outcomes without signs of serious pathology.[5]
  • Acetaminophen: the 2007 ACP/APS and 2015 Canadian guidelines recommended it first-line, and guidelines remain divided (8 of 14 for, 5 of 14 against in a 2018 overview).[4][7] Cochrane and JAMA 2026 evidence shows no benefit in acute LBP.[8][2]
  • Opioids: 13 of 15 guidelines in the 2018 overview recommended weak opioids for short periods.[7] A 2026 systematic review found no clear advantage over placebo and increased harm.[5]
  • Nonpharmacologic therapy first: heat, manipulation, massage, and acupuncture for acute LBP; exercise and psychological therapies for chronic LBP.[2]
  • Stratified thinking: psychosocial predictors identify patients at risk of chronicity.[5]

Areas of uncertainty and controversy

  • Proportion nonspecific: about 90% (JAMA 2026) versus 80–90% (NEJM 2022).
  • Duration cutoffs: acute is <6 weeks in recent reviews and <4 weeks in ACP 2017.[4] Referral thresholds range from 4 weeks to 2 years.[7]
  • Red-flag accuracy: few red flags are individually informative for ruling serious spine pathology in or out, and data on combinations are limited.[5][2]
  • Imaging timing in persistent pain: AFP 2025 advises reassessment with imaging and laboratory evaluation beyond 8 weeks, whereas JAMA 2026 advises against routine imaging for nonspecific LBP of any duration.[10][2]
  • Guideline disagreement on treatments: for chronic LBP, ACP recommends antidepressants while NICE and WHO recommend against. For acute LBP, ACP recommends acupuncture while NICE recommends against. Electrotherapy is recommended against wherever addressed.[2] A 2024 comparison of recent guidelines found selective coverage across guidelines.[11]
  • Medication evidence: optimal dose, frequency, duration, and long-term harms are not well studied, and many estimates are imprecise.[5] A network meta-analysis found the comparative effectiveness and safety of analgesics for acute LBP uncertain.[12]
  • Treatment trials: many pool mixed-duration populations, limiting extrapolation to acute versus chronic LBP.[4]
  • Cost-effectiveness: limited data for imaging and interventions.[5]

Clinical pearls

  • About 9 in 10 patients seen in practice have nonspecific LBP, and serious pathology is uncommon.
  • Reassurance and education about the expected course are core initial management. About 72% of acute episodes recover by 12 months, so more than a quarter do not.
  • In acute LBP, psychosocial factors were the best-supported predictors of persistent disabling LBP.
  • Cancer history, saddle anesthesia, urinary retention, procedure-related infection, and age are the strongest red-flag predictors.
  • New urinary retention, saddle anesthesia, or progressive weakness needs immediate MRI and neurosurgical evaluation.
  • Imaging without red flags does not improve outcomes and can trigger unnecessary testing through incidental findings.

Common pitfalls

  • Ordering imaging for nonspecific LBP "to reassure" or on patient request.
  • Treating degenerative imaging findings as the pain cause.
  • Over-relying on any single red flag, or missing urinary retention, saddle anesthesia, or progressive weakness.
  • Recommending bed rest or work absence by default.
  • Prescribing opioids, benzodiazepines, or acetaminophen alone as default therapy for acute LBP.
  • Mixing duration definitions across sources without stating the cutoff used.
  • Omitting psychosocial assessment, leaving patients at risk of chronicity unidentified.
  • Failing to reconsider the diagnosis in pain persisting beyond 8 weeks.

References

  1. ↑ 1.0 1.1 1.2 1.3 Chiarotto, Alessandro, and Bart W. Koes. "Nonspecific Low Back Pain." New England Journal of Medicine, 2022.
  2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 Cashin, Aidan G., Roger Chou, Melissa B. Weimer, and James H. McAuley. "Low Back Pain: A Review." JAMA, 14 July 2026.
  3. ↑ GBD 2021 Low Back Pain Collaborators. "Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050." Lancet Rheumatology, 2023. PMID 37273833.
  4. ↑ 4.0 4.1 4.2 4.3 Hanna, Magdi, Serge Perrot, and Giustino Varrassi. "Critical Appraisal of Current Acute LBP Management and the Role of a Multimodal Analgesia: A Narrative Review." Pain and Therapy, 2023.
  5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 5.13 5.14 5.15 Skelly, Andrea C., et al. "Assessment and Treatment of Acute Low Back Pain (ALBP): A Systematic Review." Pain Medicine, 2026. PMID 42799684. https://pubmed.ncbi.nlm.nih.gov/42799684/
  6. ↑ 6.0 6.1 6.2 Verhagen, Arianne P., et al. "Red flags presented in current low back pain guidelines: a review." European Spine Journal, 2016.
  7. ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 Oliveira, Crystian B., et al. "Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview." European Spine Journal, 2018.
  8. ↑ 8.0 8.1 Cashin, Aidan G., et al. "Pharmacological Treatments for Low Back Pain in Adults: An Overview of Cochrane Reviews." Cochrane Database of Systematic Reviews, 2023. PMID 37014979.
  9. ↑ Traeger, Adrian C., Amir Qaseem, and James H. McAuley. "Low Back Pain." JAMA, 2021.
  10. ↑ 10.0 10.1 Earwood, J. S., N. A. Doles, and R. S. Russell. "Acute Low Back Pain: Diagnosis and Management." American Family Physician, 2025. PMID 41252835. https://pubmed.ncbi.nlm.nih.gov/41252835/
  11. ↑ Zhou, Tianyu, Dalia Salman, and Alison H. McGregor. "Recent clinical practice guidelines for the management of low back pain: a global comparison." BMC Musculoskeletal Disorders, 2024.
  12. ↑ Wewege, Michael A., et al. "Comparative effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain: systematic review and network meta-analysis." BMJ, 2023. PMID 36948512.

Template:WH Template:WS ```